SGPL1 and cystic fibrosis: Indeed, CF patients present multiple defects in the sphingolipid metabolism, including reduced levels of S1P in the lung (Veltman et al., 2016), and an inhibitor of SPL could normalize the immune response upon challenge with inflammatory stimuli in a murine model of CF (Veltman et al., 2016).